Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians.

MLA

Yang, Jingyan, et al. “Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians.” BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 36, no. 1, Jan. 2022, pp. 71–83. EBSCOhost, https://doi.org/10.1007/s40259-021-00509-3.

APA

Yang, J., Blinzler, K., Lankin, J., Vijayakumar, S., Maculaitis, M. C., & Shelbaya, A. (2022). Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 36(1), 71–83. https://doi.org/10.1007/s40259-021-00509-3

Chicago

Yang, Jingyan, Kelly Blinzler, Joshua Lankin, Sapna Vijayakumar, Martine C Maculaitis, and Ahmed Shelbaya. 2022. “Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians.” BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 36 (1): 71–83. doi:10.1007/s40259-021-00509-3.